Last reviewed · How we verify
VBC101
At a glance
| Generic name | VBC101 |
|---|---|
| Sponsor | VelaVigo Bio Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VBC101 CI brief — competitive landscape report
- VBC101 updates RSS · CI watch RSS
- VelaVigo Bio Inc portfolio CI